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Abstract
Background: Recurrent benign 6th nerve palsy in the paediatric age group is uncommon, but has been described
following viral and bacterial infections. It has also been temporally associated with immunization, but has not been
previously described following two different live attenuated vaccines.
Case presentation: A case is presented of a 12 month old Caucasian boy with recurrent benign 6th nerve palsy
following measles-mumps-rubella and varicella vaccines, given on separate occasions with complete recovery
following each episode. No alternate underlying etiology was identified despite extensive investigations and review.
Conclusions: The majority of benign 6th nerve palsies do not have a sinister cause and have an excellent
prognosis, with recovery expected in most cases. The exact pathophysiology is unknown, although hypotheses
including autoimmune mechanisms and direct viral invasion could explain the pathophysiology behind
immunization related nerve palsies. It is important to rule out other aetiologies with thorough history, physical
examination and investigations. There is limited information in the literature regarding the safety of a repeat dose of
a live vaccine in this setting. Future immunizations should be considered on a case-by-case basis.
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Background
The age and gender-adjusted incidence of sixth nerve
palsy is 11.3 per 100,000, with 26% of cases with undeter-
mined or benign aetiology [1]. Within the paediatric age
group, acute benign sixth nerve palsy accounts for 9-14%
of all sixth nerve palsies [2]. It is of presumed inflamma-
tory etiology, and may follow viral and bacterial infections
such as Varicella zoster, Epstein-Barr, Cytomegalovirus,
Staphylococcus aureus, Coxiella burnetti and Borrelia
burgdorferi [3-6]. Recurrent palsies are rarer still, with pre-
sumed similar etiology. Recurrence has been temporally
associated with immunization [4], including both inacti-
vated and live attenuated viral vaccines (Table 1). It has
not previously been described following two different live
attenuated vaccines. A case of recurrent sixth nerve palsy
following different live attenuated vaccines is reported and
discussed.
Case presentation
A previously healthy 12 month old boy presented to hos-
pital with a right 6th nerve palsy seven days after his rou-
tine 12 month immunizations: measles, mumps, rubella
(MMR) (PriorixW, GSK) and Haemophilus influenzae
type b (Hib) – Hepatitis B (ComvaxW, Merck). He had
been well for the first four days post-immunization, but
then noted by his grandparents to have a “squint” and
appear lethargic. He presented for medical attention on
day seven post-vaccination because of persistent con-
cerns about his unusual eye movements.
Two months earlier he had received his second catch-
up dose of 7-valent pneumococcal conjugate vaccination
(PrevenarW, Wyeth Vaccines) and meningococcal group
C conjugate vaccine (MeningitecW, Wyeth Vaccines). He
had experienced no adverse events from any of his previ-
ous vaccinations, which were up to date for his age on the
routine Australian National Immunization Program sched-
ule [12]. He had a past history of emergency delivery at
36 weeks gestation by caesarean section for twin-twin
transfusion following a twin pregnancy conceived by in-
vitro fertilization. There were no significant neonatal pro-
blems and he was developmentally age appropriate.
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Table 1 Clinical characteristics of patients with benign 3rd and 6th nerve palsy post-immunization
Authors Age/Gender/Side of paralysis Vaccine Type CN Time-post Vaccine Investigations Outcome
Werner et al. [5] 1 yr 3 mths/F/L MMR VI 10 days CT Brain Resolved over 3 months
0 yr 8 mths/F/L DPT VI 6 weeks Nil Resolved over 6 months
DPT Booster VI 3mths Nil Resolved over 2 months
McCormick et al. [7] 1 yr 1 mth/F/L MMR VI 1 week FBE, CRP, Anti-Nuclear Antibody (ANA), Measles and
mumps serum titers, Anti-Mitochondrial antibody,
blood cultures, serum rotavirus titer
Resolved over 8 weeks
Feces culture for parasites and C difficile
CT Brain
Leidermann et al. [8] 1 yr 5 mths/M/R Influenza VI 3 weeks MRI Brain (T1, T2, Flair) Initial 10–20 degree incomitant
esotropia with limitation of abduction
12 weeks – 10 degree esotropia
in R gaze
7 months – residual motility deficit
Sturm et al. [3] 6 mths/M/R DPT, Polio, Hib VI 6 months MRI Brain Resolved at 5 days
Mahoney et al. [9] 1 yr 8 mths/M/L DPT, Hib VI 3 weeks MRI, AchRab Improving but incomplete
2 yr 7 mths/M/L VZV VI 2.5 weeks
Manzotti et al. [10] 20mths/M/L MMR III 3 weeks FBE, UEC Resolved at 20 days
CMV, EBV, HSV,
VZV, Parvo B19, Influenza, Parainfluenza, RSV titers
Electroencephalography, MRI brain
Chan et al. [11] 1 yr 5 mths/M/R Edmonston Measles III 2 weeks FBE, UEC, ESR, blood sugar level, CSF for protein, glucose,
viral, bacterial, Blood cultures, Serum measles titer
Resolved at 2 months
Skull x-ray, electroencephalography, CT Brain
PPD Tuberculin Skin test
Intravenous Pyelogram (IVP)
Bone marrow aspirate
FBE full blood examination, UEC urea, electrolytes, creatinine, CRP C-reactive protein, CT computed tomography, MRI magnetic resonance imaging, CMV cytomegalovirus, EBV Epstein-Barr virus, HSV herpes simplex virus,




















On admission he was afebrile, blood pressure 117/59,
pulse rate 120/min, respiratory rate 30/min and oxygen
saturation of 95%. There was no history of preceding
viral illness or prodrome and no symptoms developed
during admission. Further evaluation by a pediatric neur-
ologist and ophthalmologist confirmed an isolated right
6th nerve palsy, with no evidence of facial asymmetry.
There was mild plagiocephaly, with a head circumference
of 46.5 cm (50th centile). No ptosis was evident, and fun-
doscopic examination bilaterally was normal.
Initial blood investigations included normal full blood
examination (Hb 128 g/L; Platelets 284 x109/L; leuko-
cytes 11.1 x 109/L and normal baseline electrolytes, liver
function tests, creatinine kinase (CK) and serum calcium
levels. The erythrocyte sedimentation rate (ESR) was
normal (3 mm/hr).
Neuroimaging with magnetic resonance imaging (MRI)
and angiography (MRA) of the brain demonstrated no
intracranial abnormality. Cerebrospinal fluid (CSF) exam-
ination revealed no white cells, 89 red cells x106/L, protein
of 0.19 g/L (0.20-0.40), glucose 2.8 mmol/L (2.8-4.0) and
lactate of 1.2 mmol/L. A random blood glucose level was
6.0 mmol/l. There was no growth on CSF cultures. The
CSF opening pressure was 31 cm CSF, but this was
obtained at the third attempt at a lumbar puncture in a
screaming child, and the pressure was therefore likely arte-
factually elevated. Acetylcholine receptor antibodies were
negative (0.2 nmol/L).
The differential diagnoses with this presentation
included a post viral 6th nerve palsy, idiopathic cranial
nerve palsy, myasthenia gravis and benign intracranial
hypertension. He was initially trialed on Pyridostigmine
(MestinonW Valeant) 5 mg three times daily. This was
subsequently increased to 10 mg three times daily, but
with no change in clinical signs it was ceased. The 6th
nerve palsy persisted at one-week post vaccination, but
completely resolved spontaneously over the next six
weeks, with resolution confirmed on ophthalmology fol-
low-up.
The child then re-presented aged 20 months with a re-
current episode of a right 6th nerve palsy. On this occa-
sion it commenced followed a different live virus
vaccination – Varicella (VarivaxW Merck) given four
weeks earlier. Again, there was no viral prodrome and he
had otherwise been alert and well. He presented with
identical symptoms of a squint and was brought to hos-
pital for evaluation five weeks after immunization. Re-
peat examination by an ophthalmologist and pediatric
neurologist again confirmed an isolated 6th nerve palsy
with no evidence of papilledema. He was afebrile and
haemodynamically stable. The nerve palsy worsened over
the subsequent two days, then significantly improved
over the next 7–10 days and had entirely resolved by
5 weeks, now a total of 9 weeks post immunisation. On
this presentation, he did not have any neuro-imaging,
CSF analysis or repeat blood investigations.
Over the next 12 months the child tolerated numerous
viral infections with no recurrence of the squint or any
neurological symptoms. He had ongoing ophthalmology
review with no abnormalities noted. A follow-up with
pediatric neurology at two years of age confirmed a nor-
mal examination, with all appropriate developmental
milestones reached.
Following detailed discussion with the family it was
advised that further live attenuated vaccines not be
administered, even though the routine Australian
immunization schedule includes a MMR vaccine (2nd
dose) at 4 years of age [12]. The main reason for this ad-
vice was that no previous recurrent cases had been
reported in the scientific literature and therefore the
safety of further live attenuated vaccines in this setting
was unknown.
Discussion
By definition, a benign 6th nerve palsy is not due to a
sinister underlying cause, such as an underlying space
occupying lesion, and recovery is expected. The condi-
tion has a female predominance and the left side is most
commonly affected, in contrast to this case [13].
The condition is a known sequel of viral illnesses,
infections and immunization [4]. The majority of palsies
described as associated with immunization have involved
attenuated live vaccinations, including MMR and VZV
(see Table 1) [13]. To our knowledge, this is the first
documented case of recurrent benign 6th nerve palsy fol-
lowing two different live attenuated vaccinations.
Whilst an isolated 6th cranial nerve palsy may seem less
likely to be due to an underlying sinister cause, up to a
third of such palsies in children have a neoplastic origin
[14]. Therefore, a thorough history and physical examin-
ation is recommended, in combination with an MRI brain
scan [15]. Fasting blood glucose, complete cell count,
blood pressure evaluation, lumbar puncture and other
investigations may be warranted, but should be considered
on a case-by-case basis. Further review by a neurologist
and ophthalmologist is recommended to assess if add-
itional symptoms or clinical signs arise over time.
Despite a seemingly temporal association between benign
6th nerve palsy and immunization in children, the patho-
physiological mechanism and exact site of cellular injury
remains unclear. Hypotheses include damage from auto-
immune mediation or direct viral invasion causing demye-
lination, localized arteritis or genetic predisposition, which
could increase susceptibility to such nerve palsies [5,16].
The hypothesis that it could relate to additives in the
vaccine is unlikely. Neomycin is used as a preservative to
prevent bacterial contamination in both the MMR and
varicella vaccines, but has only been shown to contribute
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to local or systemic allergic anaphylactic reactions [17]. It
is also an additive in many of the non-live vaccines the pa-
tient received in childhood without incident and extensive
epidemiological studies have not found a link between
neurological adverse events following immunization
(AEFI) and additives or adjuvants in vaccines [18].
Autoimmune mechanisms post-vaccination may help
explain recurrent mononeuritis AEFI. Mutsch et al. pro-
posed an autoimmune cause from vaccine adjuvants
amongst other etiologies for Bell’s palsy associated with an
inactivated intra-nasal influenza vaccine [19]. Clifford et al.
reported three cases of orchitis post-measles mumps rubella
vaccine, which were possibly auto-immune related given a
short-time course to development of inflammation [20].
The typical incubation period for wild type measles in-
fection is approximately 10 days (range 7–18 days); at-
tenuation has been shown to increase the incubation
period for some vaccines including measles [21]. This is
also reflected in varicella infections, where development of
antibodies post vaccination to vaccine strain virus appear
later compared to those in wild type infection (range 10-
21 days for wild type) [22]. Mumps and rubella have incu-
bation periods of 14-25 days and 12-23 days respectively
[12]. Our patient’s incubation period was 5 days after
MMR vaccine and 28 days after varicella vaccine in his
two recurrent episodes, which therefore could possibly be
the result of a vaccine strain infection invading and affect-
ing the nerve root.
In adults, nerve palsies can be secondary to an ische-
mic mononeuropathy [23], but there was no evidence of
this on MRI and is unlikely in the pediatric age group.
They can also be triggered by inflammatory conditions
such as systemic lupus erythematous (SLE), but again
there was no evidence of such an etiology in this case,
with a normal ESR and no CSF pleocytosis.
Although the Hib-Hepatitis B vaccine was also adminis-
tered, the delayed onset (7 days) makes Hib or Hepatitis B
causation of the patient’s symptoms very unlikely and less
biologically plausible. As it is an inactivated vaccine, one
would expect to see most reactions occur within 24 hours
post immunisation.
There is limited information in the literature regarding
the safety of a repeat dose of a live vaccine in this setting.
As detailed above, a recurrent case of a nerve palsy has
been described post MMR [5,7]. A second and further
dose is recommended to increase the likelihood of sero-
conversion, but ultimately further immunizations should
be considered on an individual basis. If travel is planned
to a country endemic with measles, mumps or rubella,
serological assessment could be undertaken to determine
adequate sero-conversion. Within Australia however,
where endemic measles is eliminated, and the rates of
mumps and rubella are 0.6 and 0.15 per 100,000 per year
respectively [12], the risk of non-immunization is relatively
low. Whilst in this case it was felt appropriate to not
administer any further live-attenuated vaccines, it was
recommended to continue scheduled non-live vaccines,
including diphtheria-tetanus-acellular pertussis (dTap).
Conclusions
In general, prognosis for benign recurrent 6th nerve palsy is
excellent. The majority of patients recover full muscle func-
tion and have resolution of all symptoms [14]. Benign 6th
nerve palsy post-immunization is a rare occurrence that
generally resolves spontaneously but needs to be thoroughly
investigated and followed-up to ensure best outcome. The
exact pathophysiology is unknown but could be related to
autoimmune mechanisms or local demyelination. Future
immunizations should be considered on a case-by-case
basis.
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